InMode Ltd. (INMD)
NASDAQ: INMD · Real-Time Price · USD
13.40
+0.04 (0.30%)
Jun 18, 2026, 4:00 PM EDT - Market closed
InMode Revenue
InMode had revenue of $82.02M in the quarter ending March 31, 2026, with 5.32% growth. This brings the company's revenue in the last twelve months to $374.64M, down -4.53% year-over-year. In the year 2025, InMode had annual revenue of $370.50M, down -6.16%.
Revenue (ttm)
$374.64M
Revenue Growth
-4.53%
P/S Ratio
2.27
Revenue / Employee
$567,633
Employees
660
Market Cap
849.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 370.50M | -24.32M | -6.16% |
| Dec 31, 2024 | 394.82M | -97.23M | -19.76% |
| Dec 31, 2023 | 492.05M | 37.78M | 8.32% |
| Dec 31, 2022 | 454.27M | 96.71M | 27.05% |
| Dec 31, 2021 | 357.57M | 151.46M | 73.49% |
| Dec 31, 2020 | 206.11M | 49.75M | 31.81% |
| Dec 31, 2019 | 156.36M | 56.20M | 56.11% |
| Dec 31, 2018 | 100.16M | 46.71M | 87.37% |
| Dec 31, 2017 | 53.46M | 30.37M | 131.59% |
| Dec 31, 2016 | 23.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.66B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.03B |
| Tandem Diabetes Care | 1.03B |
| Avanos Medical | 715.90M |
| Bioventus | 576.30M |
| Artivion | 458.69M |
| SI-BONE | 206.22M |
INMD News
- 18 days ago - InMode Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - InMode names Moshik Itzkovich as CFO, succeeding Yair Malca - TheFly
- 4 weeks ago - InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer - PRNewsWire
- 5 weeks ago - InMode to Present at Upcoming Investor Conferences and Events - PRNewsWire
- 6 weeks ago - InMode price target lowered to $14 from $17 at Baird - TheFly
- 6 weeks ago - InMode price target lowered to $19 from $21 at Barclays - TheFly
- 6 weeks ago - InMode reports Q1 adjusted EPS 25c, consensus 30c - TheFly
- 6 weeks ago - InMode sees FY26 adjusted EPS $1.33-$1.38, consensus $1.45 - TheFly